Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii by Cayô, Rodrigo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2011, p. 5907–5913 Vol. 55, No. 12
0066-4804/11/$12.00 doi:10.1128/AAC.00459-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Analysis of Genes Encoding Penicillin-Binding Proteins in Clinical
Isolates of Acinetobacter baumannii†
Rodrigo Cayoˆ,1* María-Cruz Rodríguez,1§ Paula Espinal,2 Felipe Ferna´ndez-Cuenca,3
Alain A. Ocampo-Sosa,1 A´lvaro Pascual,3 Juan A. Ayala,4 Jordi Vila,2
and Luis Martínez-Martínez1,5
Service of Microbiology, University Hospital Marque´s de Valdecilla—IFIMAV,1 and Department of Molecular Biology, School of
Medicine, University of Cantabria,5 Santander, Service of Microbiology, Hospital Clinic, School of Medicine, University of
Barcelona, Barcelona,2 Service of Microbiology, University Hospital Virgen Macarena, Seville,3 and Centro de
Biología Molecular Severo Ochoa—CSIC-UAM, Campus de Cantoblanco, Madrid,4 Spain
Received 6 April 2011/Returned for modification 16 July 2011/Accepted 21 September 2011
There is limited information on the role of penicillin-binding proteins (PBPs) in the resistance of Acineto-
bacter baumannii to -lactams. This study presents an analysis of the allelic variations of PBP genes in A.
baumannii isolates. Twenty-six A. baumannii clinical isolates (susceptible or resistant to carbapenems) from
three teaching hospitals in Spain were included. The antimicrobial susceptibility profile, clonal pattern, and
genomic species identification were also evaluated. Based on the six complete genomes of A. baumannii, the PBP
genes were identified, and primers were designed for each gene. The nucleotide sequences of the genes
identified that encode PBPs and the corresponding amino acid sequences were compared with those of ATCC
17978. Seven PBP genes and one monofunctional transglycosylase (MGT) gene were identified in the six
genomes, encoding (i) four high-molecular-mass proteins (two of class A, PBP1a [ponA] and PBP1b [mrcB],
and two of class B, PBP2 [pbpA or mrdA] and PBP3 [ftsI]), (ii) three low-molecular-mass proteins (two of type
5, PBP5/6 [dacC] and PBP6b [dacD], and one of type 7 (PBP7/8 [pbpG]), and (iii) a monofunctional enzyme
(MtgA [mtgA]). Hot spot mutation regions were observed, although most of the allelic changes found translated
into silent mutations. The amino acid consensus sequences corresponding to the PBP genes in the genomes and
the clinical isolates were highly conserved. The changes found in amino acid sequences were associated with
concrete clonal patterns but were not directly related to susceptibility or resistance to -lactams. An insertion
sequence disrupting the gene encoding PBP6b was identified in an endemic carbapenem-resistant clone in one
of the participant hospitals.
Acinetobacter baumannii is an opportunistic nosocomial
pathogen responsible for a variety of serious infections, espe-
cially in intensive care units (ICU) (23, 27). Its ability to survive
on dry surfaces (6, 21, 41) and to acquire antimicrobial resis-
tance, as well as its suitability for genetic exchange, has con-
tributed to the longevity of this microorganism and its success
in causing epidemic outbreaks (19). Carbapenems are cur-
rently one of the few options for the treatment of infections
caused by multidrug-resistant A. baumannii (15). However,
since the early 1990s, the frequency of outbreaks caused by
carbapenem-resistant A. baumannii isolates has increased
worldwide (5, 16), becoming a significant public health concern
(40).
The mechanisms underlying resistance to carbapenems in A.
baumannii include (i) the production of -lactamases, partic-
ularly acquired carbapenem-hydrolyzing class D -lactamases
(CHDLs) (7, 31), metallo--lactamases (30), and, in rare cases,
class A carbapenemases (32), (ii) outer membrane imperme-
ability, associated with the loss or decreased expression of
porins (25), and probably (iii) the overproduction of efflux
pumps (20). However, there is limited information on the role
of penicillin-binding proteins (PBPs) in this phenotype in A.
baumannii (12, 13, 26).
PBPs are a family of enzymes that share an evolutionary
origin. These enzymes catalyze the synthesis of peptidoglycan,
the primary component of the bacterial cell wall, and are also
associated with cell morphogenesis and the cell division com-
plex (33). PBPs have been classified into two groups, the high-
molecular-mass (HMM) and low-molecular-mass (LMM)
PBPs, according to their apparent molecular weights on so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels, their amino acid sequences, and their enzymatic
and cellular functions (4, 14, 17, 33). The HMM PBPs can be
divided into class A (transpeptidase/glycosyltransferase activi-
ties) (2, 3) and class B (transpeptidase activity, elongase activ-
ity, or divisome) (10, 29) PBPs, depending on the structure of
their N-terminal domains (33). The LMM PBPs, or class C
PBPs, are D,D-carboxypeptidases and/or endopeptidases in-
volved in cell separation or peptidoglycan maturation or recy-
cling (14). The monofunctional transglycosylases (MGTs), a
group of enzymes present in some bacteria, have a single gly-
cosyltransferase domain similar to those of class A PBPs, and
their function is still unknown (35).
This study aimed to determine the nucleotide sequences of
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the genes encoding PBPs in A. baumannii and to analyze their
allelic variations in isolates susceptible or resistant to -lac-
tams.
(This work was presented in part as an oral presentation at
the 8th International Symposium on the Biology of Acineto-
bacter in Rome, Italy, 2010.)
MATERIALS AND METHODS
Bacterial isolates. A total of 26 nonduplicate A. baumannii clinical isolates
presenting different carbapenem susceptibility profiles were collected in three
teaching hospitals in Spain: the University Hospital Marque´s de Valdecilla,
Santander (n  12), the Hospital Clínic, Barcelona (n  12), and the University
Hospital Virgen Macarena, Seville (n  2) (Table 1). The two isolates from the
third hospital have been described previously (12). These isolates were repre-
sentative of the most prevalent clones in each institution. Presumptive identifi-
cation of the isolates as A. baumannii was carried out by amplifying the complete
open reading frame of the blaOXA-51-like gene, which is considered chromo-
somally intrinsic to A. baumannii (31), using primers OXA-69A and OXA-69B as
described previously (18). Both primers were also used to detect the presence of
ISAba1 upstream of the blaOXA-51-like gene (18). Amplified rRNA gene restric-
tion analysis (ARDRA), using the CfoI, AluI, MboI, RsaI, and MspI enzymes,
was carried out as described previously (39) to confirm the genomic species
identification of A. baumannii. The reference strain A. baumannii RUH-134 (11)
was included as a control for both genomic identification and PCR amplification
of PBP genes.
Testing of susceptibility to antimicrobial drugs. Tigecycline and colistin MICs
were determined at the three participating centers by broth microdilution ac-
cording to Clinical and Laboratory Standards Institute (CLSI) guidelines (8).
The MICs of imipenem, meropenem, cefepime, ceftazidime, ceftriaxone, cefo-
taxime, aztreonam, amikacin, gentamicin, minocycline, and ciprofloxacin were
also determined by microdilution for the isolates from the Hospital Clínic and
the University Hospital Virgen Macarena, but for the isolates from the Univer-
sity Hospital Marque´s de Valdecilla, the MICs of these drugs were determined
with Etest strips according to the manufacturer’s (AB bioMe´rieux, Solna, Swe-
den) recommendations,. The results for tigecycline were interpreted according to
the U.S. Food and Drug Administration (FDA) breakpoints for Enterobacteria-
ceae (for susceptibility, 2 g/ml; for intermediacy, 4 g/ml; for resistance, 8
g/ml), and the results for the other antimicrobial agents tested were interpreted
according to the CLSI breakpoints (9). Pseudomonas aeruginosa ATCC 27853
and Escherichia coli ATCC 25922 were used as quality control strains.
Molecular typing by PFGE. The clonal relationships of the A. baumannii
isolates were determined by pulsed-field gel electrophoresis (PFGE) using the
ApaI restriction enzyme (Roche Diagnostics, Indianapolis, IN), as described
elsewhere (34). The restriction fragments were separated on 1% (wt/vol) agarose
gels in 0.5% Tris-borate-EDTA (TBE) buffer in a CHEF-DR (contour-clamped
homogeneous electric field–dynamically regulated) III Mapper electrophoresis
system (Bio-Rad Laboratories, Richmond, CA) for 19 h at 14°C using a pulse
ramping rate changing from 5 to 20 s at 6 V/cm. DNA fingerprints were inter-
preted as recommended by Tenover et al. (37). The reference strains A. bau-
mannii RUH-875 and RUH-134 (11), representatives of major international
clones I and II, respectively, were also used as comparators.
Identification of PBP genes. The genes encoding PBPs were identified on the
basis of the six complete genomes of A. baumannii that had been deposited in
GenBank by the time this study was started. The following organisms were
considered: A. baumannii strains AB0057 (accession no. NC_011586), ATCC
17978 (accession no. NC_009085), SDF (accession no. NC_010400), AYE (ac-
cession no. NC_010410), ACICU (accession no. NC_010611), and AB307-0294
(accession no. NC_011595). Consensus sequences were obtained for each PBP
gene identified, and a series of primers for PCR amplification and sequencing
was designed, as listed in Table S1 in the supplemental material. The A.
baumannii genomes deposited in GenBank after the beginning of this study
were also considered for comparison and analysis of the PBP genes. These
genomes include those of A. baumannii strains AB056 (accession no.
NZ_ADGZ01000571), AB058 (accession no. NZ_ADHA01000108), AB059 (ac-
cession no. NZ_ADHB01000264), AB900 (accession no. NZ_ABXK01000007),
and ATCC 19606 (accession no. NZ_ACQB00000000).
Analysis of the PBP genes in A. baumannii clinical isolates. Genomic DNA
from clinical isolates was extracted with InstaGene Matrix (Bio-Rad Laborato-
ries, Hercules, CA) according to the manufacturer’s recommendations. PBP
genes were amplified by PCR under the following conditions: 95°C for 5 min,
followed by 35 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 1 to 3 min,
according to the amplicon size, and finally 72°C for 7 min. PCR products were
analyzed on 1% (wt/vol) agarose gels stained with ethidium bromide. PCR
products were purified by using a High Pure PCR product purification kit (Roche
Diagnostics, Mannheim, Germany). Bidirectional DNA sequencing was per-
formed by Macrogen Inc. (Seoul, South Korea). Each PBP gene was named and
TABLE 1. Genetic characterization of the 26 A. baumannii clinical isolates
Strain Hospitala/city PFGEclone
MIC (g/ml) of the following drugb:
Oxacillinase type(s)
IPM MEM FEP CAZ CRO CTX ATM AMK GEN MIN CIP TGC CST
HUMV-823 HUMV/Santander A 32 32 32 32 32 32 16 16 8 8 2 1 0.5 OXA-51-like  ISAba1
HUMV-1175 HUMV/Santander A1 32 32 32 32 32 32 16 16 8 8 2 1 0.5 OXA-51-like  ISAba1
HUMV-3743 HUMV/Santander A2 32 32 32 32 32 32 16 16 8 8 2 1 0.5 OXA-51-like  ISAba1
HUMV-1102 HUMV/Santander B 2 2 8 16 32 32 16 8 4 4 2 1 1 OXA-51-like
HUMV-2790 HUMV/Santander B 1 1 8 32 32 32 16 8 4 4 2 1 1 OXA-51-like
HUMV-1319 HUMV/Santander C 32 32 32 16 32 32 16 16 8 2 2 1 0.5 OXA-51-like, OXA-24
HUMV-5118 HUMV/Santander C 32 32 32 32 32 32 16 16 8 1 2 1 0.5 OXA-51-like, OXA-24
HUMV-2471 HUMV/Santander D 32 32 8 8 4 4 8 16 8 2 2 0.25 0.25 OXA-51-like, OXA-24
HUMV-4066 HUMV/Santander D 32 32 32 8 32 32 16 16 8 2 2 0.25 0.5 OXA-51-like, OXA-24
HUMV-6457 HUMV/Santander D 32 32 32 16 8 8 16 8 4 2 2 0.25 0.5 OXA-51-like, OXA-24
HUMV-2120 HUMV/Santander E 0.25 0.25 4 8 8 8 16 8 4 1 0.125 0.5 0.5 OXA-51-like
HUMV-4674 HUMV/Santander F 0.5 0.5 8 8 8 8 16 8 4 0.5 1 2 0.5 OXA-51-like
HC-360 HC/Barcelona G 1 2 32 32 32 32 16 16 8 2 2 1 0.25 OXA-51-like
HC-3581 HC/Barcelona G 1 2 32 32 32 32 16 16 8 2 2 1 0.25 OXA-51-like
HC-4249 HC/Barcelona G 32 32 32 32 32 32 16 16 8 0.5 2 0.5 0.5 OXA-51-like, OXA-24
HC-4275 HC/Barcelona G 32 32 32 32 32 32 16 16 8 1 2 1 0.125 OXA-51-like  ISAba1,
OXA-24
HC-60 HC/Barcelona H 1 4 32 8 16 16 16 16 8 0.5 1 1 0.125 OXA-51-like
HC-3343 HC/Barcelona H 1 4 32 8 16 16 16 16 8 0.5 1 1 0.125 OXA-51-like
HC-4256 HC/Barcelona H 32 32 16 8 32 32 16 8 8 0.5 1 0.5 0.25 OXA-51-like, OXA-24
HC-3202 HC/Barcelona H 32 32 32 32 32 32 16 16 8 2 2 1 0.25 OXA-51-like, OXA-24
HC-771 HC/Barcelona I 1 4 16 32 32 32 16 16 8 8 2 0.5 0.25 OXA-51-like
HC-769 HC/Barcelona I 1 8 16 32 32 32 16 16 8 8 2 1 0.25 OXA-51-like
HC-181 HC/Barcelona I 32 32 16 32 32 32 16 16 8 8 2 0.5 0.25 OXA-51-like  ISAba1
HC-1959 HC/Barcelona I 32 32 32 32 32 32 16 16 8 8 2 0.5 0.25 OXA-51-like  ISAba1
HUS-31 HUVM/Seville J 0.25 0.5 32 16 32 32 16 16 8 2 2 2 0.25 OXA-51-like
HUS-457 HUVM/Seville K 4 4 4 16 32 32 16 16 8 0.5 2 0.5 0.125 OXA-51-like
a HUMV, Hospital Universitario Marqués de Valdecilla; HC, Hospital Clinic; HUVM, Hospital Universitario Virgen Macarena.
b IPM, imipenem; MEM, meropenem; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; ATM, aztreonam; AMK, amikacin; GEN, gentamicin;
MIN, minocycline; CIP, ciprofloxacin; TGC, tigecycline; CST, colistin.
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classified on the basis of homology with other PBP sequences from different
microorganisms deposited in GenBank, as well as by the recognition of con-
served motifs. All PBP sequences were compared with those of A. baumannii
ATCC 17978 (1).
Nucleotide sequence accession numbers. The nucleotide sequences of the PBP
genes of the A. baumannii clinical isolates in this study have been deposited in
the GenBank nucleotide sequence database and were assigned the following
accession numbers, according to each PBP/MTG gene and strain: for ponA,
JF746077 to JF746102; for mrcB, JF746103 to JF746128; for pbpA, JF745973 to
JF745998; for ftsI, JF745999 to JF746024; for dacC, JF746025 to JF746050; for
dacD, JF746051 to JF746074; for pbpG, JF746129 to JF746154; and for mtgA,
JF745947 to JF745972.
RESULTS
PBP genes in A. baumannii. Seven PBP genes and one MTG
gene were identified in the six A. baumannii genomes analyzed
in this study (Table 2). Four HMM PBPs were found: PBP1a
(encoded by ponA), PBP1b (mrcB), PBP2 (pbpA or mrdA), and
PBP3 (ftsI). According to their N-terminal domains, they were
assigned to class A (PBP1a and PBP1b) or class B (PBP2 and
PBP3). Sequence alignment revealed the five conserved mo-
tifs [EDXXFXXHXG, GXSTXX(M/Q)QXXK, RKXXE,
KXXIXXYXN, and RXXXXL (where X is any amino acid)] of
the glycosyltransferase N-terminal domain in both HMM class
A PBPs (Fig. 1A). In the C-terminal penicillin-binding (PB)
domain, with transpeptidase activity, the residue following mo-
tif 3 [K(T/S)GT] was a threonine in class A PBPs (KTGTT for
PBP1a and KSGTT for PBP1b) and an alanine in class B PBPs
(KTGTA), as expected (Fig. 1B). The HMM class A PBPs,
PBP1a and PBP1b, are the major transglycosylases-transpep-
tidases in A. baumannii and are probably involved in the elon-
gation of non-cross-linked glycan chains of peptidoglycan.
The presence of an aspartic acid residue at the third position
of motif 2 (SXD) in the active site of PBP2 (pbpA) and the
presence of an asparagine residue at the same position in PBP3
confirmed the classification of these PBPs into subclasses B2
and B3, respectively (Fig. 1C). Both PBP2 and PBP3 are
monofunctional transpeptidases. PBP2 is a member of subclass
B2, a group of proteins involved in cell elongation. PBP3, as a
member of subclass B3, is probably associated with cell divi-
sion. The fstI gene was localized in the A. baumannii genomes
in an operon with the mraW, mraY, ftsL, murE, and murF
genes, which are associated with the divisome. MtgA (encoded
by mtgA) is a monofunctional transglycosylase with a glycosyl-
transferase domain similar to those of PBP1a and PBP1b.
Three LMM PBPs have been found in A. baumannii: PBP5/6
(encoded by dacC), PBP6b (dacD), and PBP7/8 (pbpG). These
LMM PBPs are associated with cell separation and the matu-
ration or recycling of peptidoglycan. Analysis of the genes
encoding PBP5 and PBP6 in A. baumannii genomes showed
that they are identical at the nucleotide and amino acid levels.
Thus, this PBP is referred to as PBP5/6 (dacC). This PBP and
PBP6b (dacD) were classified as class C type 5 PBPs, and both
are presumably D-Ala-D-Ala-carboxypeptidases. PBP7/8
(pbpG) is a class C type 7 PBP with putative endopeptidase
activity. No class C type 4 PBP genes seem to be present in A.
baumannii.
Hot spot mutations in PBP genes and -lactam resistance.
The 26 clinical isolates were identified as A. baumannii by
ARDRA, and all isolates carried a blaOXA-51 allele (Table 1).
PFGE profile analysis revealed that the 26 isolates were cate-
gorized into 11 different clones. All A. baumannii isolates were
susceptible to colistin and tigecycline, with MICs ranging from
0.25 to 1 g/ml and 0.5 to 1 g/ml, respectively. Minocycline
also showed good coverage against the A. baumannii isolates
tested (73.1% susceptibility; MIC at which 50% of isolates
were inhibited [MIC50], 2 g/ml). High resistance rates were
observed for expanded-spectrum cephalosporins (MIC50,
32 g/ml), cefepime (MIC50, 32 g/ml), and aztreonam
(MIC50, 16 g/ml). The MICs of imipenem and mero-
penem ranged from 0.25 to 32 g/ml, and for 53% of the
isolates, the MICs of both these antimicrobial agents were 32
g/ml. The majority of the isolates were resistant to cipro-
floxacin (MIC50, 2 g/ml) and aminoglycosides (MIC50s,
8 g/ml for gentamicin and 16 g/ml for amikacin). All
the A. baumannii isolates resistant to carbapenems (n  14)
carried the plasmid-borne carbapenemase gene blaOXA-24 or
the insertion sequence ISAba1 upstream of the chromo-
somal blaOXA-51-like gene and/or AmpC (data not shown).
Analysis of the nucleotide sequences of the seven PBP genes
TABLE 2. The penicillin-binding proteins of A. baumannii
PBP (gene) PBP classificationa Molecular function Possible physiologicalfunctionb
% identityc with:
Pseudomonas
aeruginosa
Escherichia
coli
PBP1a (ponA) HMM class A (subclass A1) Transglycosylase and transpeptidase Peptidoglycan synthesis 43 36
PBP1b (mrcB) HMM class A (subclass A2) Transglycosylase and transpeptidase Peptidoglycan synthesis 42 32
MtgA (mtgA) Monofunctional enzymes
(MGTs)
Monofunctional transglycosylase Unknown 34 32
PBP2 (mrdA, also
called pbpA)
HMM class B (subclass B2) Transpeptidase Cell elongation 45 39
PBP3 (ftsI) HMM class B (subclass B3) Transpeptidase Septum formation
(cell division)
39 39
PBP5/6 (dacC) LMM class C (type 5) D-Ala-D-Ala-carboxypeptidase Unknown 48 40
PBP6b (dacD) LMM class C (type 5) D-Ala-D-Ala-carboxypeptidase Unknown 31
PBP7/8 (pbpG) LMM class C (type 7) Endopeptidase Unknown 38 34
a HMM, high molecular mass; LMM, low molecular mass.
b Enzymatic activities and functions predicted by sequence homology analysis.
c Amino acid sequence homology with the PBP and MGT proteins from the genomes of P. aeruginosa strain PA7 (accession no. NC_009656), E. coli O157:H7 strain
EDL933 (accession no. NC_002655.2), and A. baumannii strain SDF (accession no. NC_010400). Analysis was performed using CLUSTAL W2 (http://www.ebi.ac.uk
/Tools/msa/clustalw2/zurlx).
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and one MGT gene in the A. baumannii clinical isolates re-
vealed specific hot spot mutation regions in all genes. How-
ever, most of the allelic variations observed were silent muta-
tions (data not shown). The main changes in the different PBP
genes relative to the sequences of strain ATCC 17978 are
shown in Table 3. Although a few mutations were found in the
amino acid sequences of the PBPs, none of these mutations
could be related to -lactam resistance. The observed changes
in the amino acid sequence were associated with specific clonal
patterns, and in general, the same mutations were observed in
organisms from the different hospitals as well as in the 10
genomes already sequenced (Table 4). Interestingly, compari-
son of the amino acid consensus sequence corresponding to
each PBP gene in the A. baumannii genomes deposited in
GenBank with the corresponding amino acid consensus se-
quence of the 26 A. baumannii clinical isolates showed that
these genes were highly conserved (identity, 99.6% to 100.0%).
In two isolates (HUMV-1319 and HUMV-5118) of an en-
demic carbapenem-resistant clone (MIC,32 g/ml) from one
of the participating centers, PCR amplification of the carboxy-
peptidase PBP6b gene showed a fragment of 2,410 bp instead
of the expected 1,320 bp. Sequencing of this amplicon indi-
cated the presence of an insertion sequence (IS) disrupting the
PBP6b gene. This IS was identical to an IS30 family trans-
posase found in the genome of A. baumannii strain ACICU
and was similar to ISAba125, differing only in His222Tyr codons
in the transposase gene. Two imperfect inverted repeats (IR-L
[AAACTTGAAGTCGACA] and IR-R [TGTCGCACCTCA
TGTTT]) bordering the transposase gene were also identified.
The IS was not found in the carO gene in these two isolates
(data not shown).
DISCUSSION
PBPs are involved in the metabolism of peptidoglycan, an
essential component of the bacterial cell wall (33). -Lactams
mimic the D-Ala-D-Ala dipeptide and act as suicide inhibitors
binding covalently to the PBPs (45). Inhibition of PBPs causes
instability in the cell wall, resulting in growth inhibition or lysis
(42). In this study, seven PBP genes and one MGT gene were
found in the genomes of several A. baumannii strains, encoding
PBP1a, PBP1b, PBP2, PBP3, PBP5/6, PBP6b, PBP7/8, and
FIG. 1. Identification of the conserved motifs in the consensus sequences encoded by the HMM PBP genes of A. baumannii genomes used for
the classification of PBPs, according to the work of Sauvage et al. (33). (A) Localization of the five characteristic conserved motifs of the N-terminal
domain (boxed) in both HMM class A PBPs, PBP1a and PBP1b. (B) Arrows indicate differences in motif 3 of the C-terminal domain (underlined)
between the HMM class A and class B PBPs. (C) Arrows indicate the motif 2 residues in the third position of the active site of the HMM class
B PBPs, used to divide these PBPs into subclasses B2 and B3. The first two residues of the active site are underlined.
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MtgA. The amino acid sequences of these PBPs in the A.
baumannii clinical isolates were compared with those in strain
ATCC 17978. This strain was isolated in the early 1950s (1),
prior to the development of the majority of the antimicrobial
agents used in clinical practice. This comparison showed that
PBP genes are highly conserved in all A. baumannii strains
analyzed. The few point mutations observed could not be as-
sociated with carbapenem resistance, since they were found in
both susceptible and resistant strains. Some point mutations
were observed in specific isolates, especially in the genome of
strain SDF (Table 4), a multisusceptible A. baumannii strain. It
is most probable that these variations are associated with
clonal patterns.
PBPs with low affinity for -lactams had been described for
Acinetobacter spp. (13, 26, 38). Gehrlein et al. (13) described
seven PBPs in an A. baumannii clinical strain with apparent
molecular sizes of 94, 84, 65, 61, 48, 40, and 24 kDa, based on
phenotypic assays; the first six could be identified as PBP1a
(94.74 kDa), PBP1b (88.26 kDa), PBP2 (74.42 kDa), PBP3
(67.66 kDa), PBP5/6 (48.84 kDa), and PBP6 (41.78 kDa), re-
spectively, but the last PBP did not correlate with PBP7/8
(36.86 kDa). They also observed that imipenem could select in
vitro for a resistant A. baumannii mutant showing a complex
reorganization of PBPs. Because no alterations in outer mem-
brane proteins (OMPs) or in -lactamase production were
detected in the imipenem-resistant mutant, the authors asso-
ciated the alterations in PBP profiles with the observed imi-
penem resistance. In another study, Obara and Nakae (26)
evaluated 12 imipenem-susceptible strains of Acinetobacter
calcoaceticus and detected six PBP bands of 94 (PBPla), 92
(PBPlb), 86 (PBPlc), 74 (PBP2), 59 (PBP3), and 42 (PBP4)
kDa. In vitro-selected mutants resistant to cefoxitin, cefopera-
zone, or ceftazidime showed reduced expression of porins, as
well as alterations in PBP expression and/or affinity for -lac-
tams. In another study, an imipenem-resistant nosocomial
strain of A. baumannii showing PBPs with low affinity for
-lactamase inhibitors, especially clavulanic acid, was reported
(38). This study also showed that sulbactam bound to PBPs
better than tazobactam, even in imipenem-resistant strains,
which may explain the satisfactory in vitro activity of sulbac-
tam against some multidrug-resistant A. baumannii isolates
(22, 28).
Ferna´ndez-Cuenca et al. (12) used 12% SDS-PAGE gels
marked with 125I-labeled ampicillin to evaluate the PBP pro-
files of two groups of A. baumannii isolates with imipenem and
meropenem MICs of 0.25 to 2 g/ml and 4 to 32 g/ml, re-
spectively. Isolates HUS-31 and HUS-457, included in the
present study, are representative of these two groups, respec-
tively. Isolates with carbapenem MICs of 4 g/ml showed
reduced expression of a 73.2-kDa PBP named PBP2 (which
may correspond to the PBP2 identified in this study [74.42
kDa]), associated with the production of several -lactamases,
including oxacillinases (which has been confirmed in the pres-
ent study), and, in some isolates, with the loss of a 22.5-kDa
porin. We have not observed any mutations in PBP2 (or any
other PBP) of strain HUS-457, suggesting that regulatory
mechanisms could be involved in the reported decreased ex-
pression of the 73.2-kDa protein in this isolate.
An IS has been found to disrupt the dacD gene (encoding
PBP6b) in two isolates of a carbapenem-resistant endemic
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clone. This IS is similar to ISAba125, which was previously
reported to disrupt the carO gene (25), coding for a porin
associated with resistance to carbapenems in A. baumannii.
Although E. coli mutants lacking one or all of the LMM PBPs
failed to substantially affect cell division or elongation (14),
Moya et al. (24) have reported that in P. aeruginosa, inactiva-
tion of the dacB gene (encoding the nonessential PBP4, but
absent in A. baumannii) is associated with a complex high-level
-lactam resistance, triggering ampC overproduction and the
specific activation of the CreBC two-component regulator,
which also activates the expression of -lactamase in an Aero-
monas PBP4-like mutant (36). Zamorano et al. (44) also
showed that dacB inactivation produced significantly higher
MICs of antipseudomonal penicillins and cephalosporins than
ampD inactivation. We may speculate that the importance of
inactivation of the PBP6 gene in carbapenem resistance might
be marginal. It was observed in only 2 of the 14 carbapenem-
resistant isolates we studied (both of which belonged to the
same clone), in which resistance can be explained by the pro-
duction of OXA-24. In fact, other OXA-24-producing isolates
are also resistant to carbapenems (Table 1), even though they
do not have an inactivated PBP6 gene. Unfortunately, attempts
to silence the dacD gene in the carbapenem-susceptible A.
baumannii strain ATCC 19606 (to verify the actual role of
PBP6b in -lactam resistance) were unsuccessful until now.
Additional studies on this topic are warranted.
Recently, Yun et al. (43) evaluated proteome regulation in
an imipenem-resistant A. baumannii strain under antibiotic
stress conditions. They observed that the levels of RND family
transporters (AdeABC and AdeJIK), the PBP genes ponA
(PBP1a), ftsI (PBP3), and dacC (PBP5/6), and, noticeably,
AmpC -lactamase were increased in the presence of imi-
penem. In contrast, repression of the OMPs OmpA and
OmpW was observed under the same conditions. These results
suggest that together such mechanisms contribute to imipenem
resistance in A. baumannii.
In the presence of efficient alternatives, such as CHDL pro-
duction and/or porin loss, the selective pressure of -lactams
against PBPs in A. baumannii may be insufficient to select for
structural changes that are directly involved in -lactam resis-
tance. On the other hand, it is possible that other complex
mechanisms associated with the regulation of PBP genes, as
well as posttranscriptional events, could cause -lactam resis-
tance in this pathogen. Our findings may represent a first step
toward understanding of the actual role of the PBPs in the
complex resistance of A. baumannii to -lactams.
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